Submit a Comment

Print

E-mail

BEVERLY, Mass. — Inotek Pharmaceuticals has begun enrolling patients in a phase 1 clinical trial evaluating the safety, tolerability and IOP-lowering potential of INO-8875, a selective adenosine-1 agonist for treating glaucoma, the company announced in a press release.

Inotek received U.S. Food and Drug Administration approval to advance the drug into clinical trials in March, the release said.

"New mechanisms for lowering IOP are needed to provide physicians with alternatives for the treatment of this chronic and progressive ocular disease — especially given the expanding population of glaucoma patients," Rudolf Baumgartner, MD, Inotek's chief medical officer, said. "Highly selective adenosine-1 receptor agonists, such as ours, may provide a meaningful new approach for the management of glaucoma."

Story continues below↓

The company also has other drugs in preclinical development for treating ophthalmic disorders, including diabetic retinopathy, age-related macular degeneration and uveitis, according to the release.